Effects of an exclusive human-milk diet in preterm neonates on early vascular aging risk factors (NEOVASC): study protocol for a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial

Wolfgang Mitterer¹ ², Christoph Binder³, Anya Blassnig-Ezeh⁴, Lorenz Auer-Hackenberg⁵, Angelika Berger³, Burkhard Simma⁵, Martin Wald⁵, Martin Lee⁶ ⁷ and Ursula Kiechl-Kohlendorfer² *

Abstract

Background: Preterm birth accounts for approximately 11% of all livebirths globally. Due to improvements in perinatal care, more than 95% of these infants now survive into adulthood. Research has indicated a robust association between prematurity and increased cardiovascular risk factors and cardiovascular mortality. While the innate adverse effects of prematurity on these outcomes have been demonstrated, therapeutic strategies on the mitigation of these concerning developments are lacking. The primary objective of the NEOVASC clinical trial is therefore to investigate whether the administration of a prolonged exclusive human-milk diet in preterm infants is capable of alleviating the harmful effects of preterm birth on the early development of cardiovascular risk factors.

Methods: The NEOVASC study is a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial conducted in four Austrian tertiary neonatal care facilities. The purpose of the present trial is to investigate the effects of a prolonged exclusive human-milk-diet devoid of bovine-milk-based food components on cardiovascular and metabolic risk factors at 1, 2, and 5 years of corrected age. Primary outcomes include assessments of fasting blood glucose levels, blood pressure levels, and the distensibility of the descending aorta using validated echocardiographic protocols at 5 years of corrected age. The test group, which consists of 200 preterm infants, will therefore be compared to a control group of 100 term-born infants and a historical control group recruited previously.

* Correspondence: ursula.kiechl-kohlendorfer@i-med.ac.at
² Department of Pediatrics II (Neonatology), Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria

Full list of author information is available at the end of the article
Discussion: Given the emerging implications of an increased cardiovascular risk profile in the potentially growing population of preterm infants, further research on the mitigation of long-term morbidities in formerly preterm infants is urgently warranted. Further optimizing preterm infants’ nutrition by removing bovine-milk-based food components may therefore be an interesting approach worth pursuing.

Trial registration: ClinicalTrials.gov NCT04413994. Registered on 4 June 2020.

Keywords: Neonatology, Prematurity, Preterm, Human milk, Human-milk-based fortifier, Cardiovascular risk

Introduction

Background

According to the World Health Organization (WHO), noncommunicable diseases (NCDs) are the world’s leading cause of death. Among NCDs, cardiovascular diseases (CVDs) are the most common ones, responsible for an estimated 17.8 million (31.8 %) deaths in 2017, and are therefore the single leading cause of global mortality [1, 2]. While family history and unhealthy lifestyle factors are undoubtedly associated with the development of CVDs, further research has identified early-life exposures as additional risk factors. Based on Barker’s “fetal origins of adult disease” hypothesis, adverse conditions in the intrauterine and perinatal environment may permanently alter physiologic circuits and organ function. Initially intended to aid survival, these adaptations may prove disadvantageous in the long-term by putting individuals at risk for the development of chronic cardiovascular and metabolic disorders [3, 4]. Recent evidence has suggested that preterm birth plays an important role in the fetal/neonatal programming of future morbidity [5] and mortality [6–9]. According to the most recent WHO estimates, preterm birth (< 37 weeks’ gestation) accounted for 10.6% of all livebirths worldwide with tendencies potentially increasing over time in middle- and high-income countries [10]. Due to advances in perinatal care [11, 12], the vast majority of these preterm infants now survive into adulthood [6–8]. However, several studies have shown an association between preterm birth and cardiovascular risk factors such as elevated blood pressure (BP) levels [13–16], hypertension [13, 17, 18], and type 1 or type 2 diabetes mellitus [19, 20], respectively. Compared with children born at term (≥ 37 weeks’ gestation), formerly preterm infants further display significantly reduced distensibility and increased stiffness of the descending abdominal aorta at preschool age [21], indicating initial signs of early vascular aging [22]. Mother’s milk is the optimal source of nutrition for all infants [23]. As for many preterm infants, the nutritional value of human milk is commonly enhanced by the use of fortifiers to meet their special needs. In cases with insufficient amounts of mother’s own or donor human milk, preterm formula is routinely used. Research has suggested potential benefits of an exclusive human-milk-based diet (i.e., the combination of mother’s own or donor human milk with human-milk-based fortifiers) on outcomes such as rates of necrotizing enterocolitis (NEC), duration of parenteral nutrition, and risk of late-onset sepsis and mortality when compared to a diet containing any bovine-milk-based products [24–27]. While the favorable effects of human milk on the development of the abovementioned cardiovascular and metabolic outcomes have been demonstrated despite methodological limitations [28, 29], no study has yet investigated the possible benefits of an exclusive human-milk-diet devoid of bovine-milk-based dietary components in preterm infants during the vulnerable preterm period on these very outcomes.

The NEOVASC study

The NEOVASC study is a multicentric, prospective, randomized, controlled, open, and parallel group clinical trial conducted in four Austrian tertiary neonatal care facilities (Medical University of Innsbruck, Paracelsus Medical University Salzburg, Medical University of Vienna, Academic Teaching Hospital Feldkirch). The purpose of the present trial is to investigate the superiority of a prolonged (until 36 weeks’ gestation) exclusive human-milk-diet devoid of bovine-milk-based food components on cardiovascular and metabolic risk factors. By following formerly preterm infants until the corrected age of 5 years, we intend to facilitate research findings on the impact of specifically targeted early dietary interventions on long-term cardiovascular health. Previous research has shown that increases in BP [30, 31], alterations in glucose homeostasis [30, 32, 33], and vascular integrity [21] are visible even in early childhood following preterm birth. Given the inverse correlation between gestational age and adulthood diabetes [20] and hypertension [13, 18], respectively, we anticipate markedly significant results should our intervention in these preterm infants prove effective.

Methods/design

Study population and eligibility

Preterm-born infants

Extremely preterm infants with a birth weight between 500 g and 1250 g will be eligible to undergo
randomization in the NEOVASC study. This particular weight range was chosen in accordance with previous clinical trials on exclusive human-milk diet [24–27]. Furthermore, written informed consent from the mother will be obtained in order to enroll participants. Exclusion criteria are birth weight < 500 g or > 1250 g, inborn errors of metabolism (e.g., galactosemia, phenylketonuria), not having been NPO or fed exclusive human-milk diet prior to enrollment, presence of major congenital malformation, presence of intestinal perforation or stage II NEC prior to enrollment, parents unwilling to sign informed consent, and lastly the inability to participate for any reason based on the study investigator’s judgment (e.g., unlikely to survive the study period).

**Term-born infants**

For the control group, term-born (≥ 37 weeks’ gestation) children with an adequate birth weight will be recruited at 5 years of age. Written informed consent will be obtained from the parent(s) or legal guardian(s) prior to enrollment. Exclusion criteria are acute and chronic illness or the unwillingness of the parent(s) to sign the informed consent form.

**Randomization, study groups, and interventions**

Randomization of preterm infants will be done electronically by the use of permuted blocks (block size = 4) within a stratified randomization. The allocation sequence will be generated by the study’s statistician and provided to the principal investigators in the form of a conventional unblinded randomization table. Stratification variables are the study site and birth weight (< 1000 g and 1000–1250 g). On the basis of ethical considerations, twins are always randomized into the same study group. Preterm neonates will be randomized to either (i) an exclusive human-milk-based diet composed of mother’s milk or pasteurized donor human milk in combination with a human-milk-based fortifier (Humenavant® +4,+6; Prolacta Bioscience, Inc.) until 36 weeks of gestation (Randomized Study Product Group) or (ii) mother’s milk or pasteurized donor human milk (as long as available) in combination with a human-milk-based fortifier (as long as human milk is available) until 32 weeks’ gestation and thereafter mother’s milk or pasteurized donor human milk with a bovine-milk-based fortifier or preterm formula (Randomized Control Group) in a 1:1 ratio. Feeding will be done by protocol in which fortification will begin when the infant is receiving 80–100 ml/kg/day of enteral nutrition. After 36 weeks’ gestation, human milk with a bovine-milk-based fortifier or preterm formula will be used in both groups. While blinding of study groups is always desirable in randomized studies, this is not possible for this study due to the nature of the intervention. As a control group, term-born age-matched infants will be included (Term-born Control Group). Infants within this control group will be recruited in kindergartens at 5 years of age. The results of the present study will further be compared to a group of very preterm infants enrolled for prior clinical studies at the Medical University of Innsbruck (Historical Control Group) [21, 30, 34]. See Figure S1 for a graphic display of the study design. The description of the overall study design is in agreement with the 2013 SPIRIT checklist (see Fig. 1).

| TIMEPOINT               | ENROLLMENT | INTERVENTION | FOLLOW-UP       |
|-------------------------|------------|--------------|-----------------|
|                         | Baseline   | Begin of fortification (80–100 ml/kg/d) | 32 weeks’ gestation | 36 weeks’ gestation | Follow-up at 1 year of corrected age | Follow-up at 2 years of corrected age | Follow-up at 5 years of age |
| Eligibility Screen      | X          |              |                 |                   |                          |
| Informed Consent        | X          |              |                 |                   |                          |
| Randomization           | X          |              |                 |                   |                          |
| **INTERVENTIONS**       |            |              |                 |                   |                          |
| Intervention i) (Randomized Study Product Group) | | | |
| Intervention ii) (Randomized Control Group) | | | |
| **ASSESSMENTS**         |            |              |                 |                   |                          |
| Micro blood samples     | X          | X            | X               |                   |                          |
| Blood samples           | X          |              |                 |                   |                          |
| Echocardiographic       | X          | X            |                 |                   |                          |
| measurements            |            |              |                 |                   |                          |
| Systolic/Diastolic blood pressure | X | X | X |
| Comparison with Term-born Control Group and Historical Control Group | X | | |

Fig. 1 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) figure of enrollment, intervention, and follow-up of preterm study participants
Study outcomes and follow-up
Outcomes include predictors and intermediate components of cardiovascular disease. Primary outcomes include assessments of the absolute difference in fasting blood glucose levels, blood pressure levels, and the distensibility of the descending aorta using validated echocardiographic protocols [21, 35] at 5 years of age. Secondary outcomes include assessments of fasting blood glucose levels and blood pressure levels at 1 and 2 years of corrected age as well as comparisons of body mass index and lipid profiles at 5 years of corrected age. Data on the clinical status of preterm infants in the study will be obtained at baseline during hospitalization as well as at routine follow-up visits at 1, 2, and 5 years of age, respectively. See Fig. 1 (SPIRIT figure) for a summary of all essential study procedures in the preterm study participants. Data from participants within the term-born control group will be obtained during a singular visit at 5 years of age. Data about birth and postnatal development from these participants will be taken from the mother-child-pass (official Austrian medical records on pregnancy, birth, and early childhood). In addition, cord blood, milk, stool, and urine samples will be obtained from preterm study participants at various points during the study. While milk samples will be used for analyses regarding osmolarity and nutritional values, all other samples will be stored at −80°C for post-study analyses. As for preterm study participants from the Medical University of Vienna, body composition using body plethysmography (Pea Pod®) will further be measured at term-equivalent and 3 and 6 months of corrected age, respectively.

Sample size and statistical analyses
A group size of 100 preterm infants per study arm is sufficient to detect a lowering in systolic blood pressure from 102 mmHg (Randomized Control Group) to 99 mmHg (Randomized Study Product Group), a reduction of fasting glucose levels from 84 to 78.5 mg/dl, and an increase in the distensibility of the descending aorta from 76 to 85 kPa$^{-1}$ × 10$^{-3}$, respectively. Based on previous experience, the principal investigators are confident to recruit the intended number of study participants within a recruitment period of 36 months. Each of these calculations was performed considering a power of 0.8 by the use of two-sample $T$-test for independent samples with homoscedastic variances. The effect size for this clinical trial was based on Cohen’s $D$ assuming an effect size of 0.4. All statistical analyses will be performed on an intention-to-treat paradigm with a significance level of 0.05. Multiple outcomes will be handled using the Benjamini-Hochberg procedure for controlling the false discovery rate. Distensibility and stiffness index $\beta$ of the descending abdominal aorta and lipid profiles will be compared between groups with two-sample $T$-tests or the Wilcoxon rank-sum test as a primary analysis at any given time point (looking at change from baseline). However, an adjusted analysis using a general linear model will incorporate the potential time trends in the results, as well as relevant covariates. Relationships between elasticity and stiffness, or lipid profiles and independent variables (sex, gestational age at birth, birth weight, ponderal index) will be studied by univariate and multivariate regression analysis. Missing data will be imputed using a multiple imputation with chained equations approach. In the event of repeated missing data over time, the simplistic last value carried forward approach may be used. However, in order to evaluate the data from a sensitivity analysis perspective, a secondary analysis on a per-protocol basis will be performed. This analysis will only consider participants who were correctly randomized and have complete data sets.

Data management
Relevant data will be obtained using an electronic data capture system. After data acquisition is completed, a clean data file for the following statistical analyses will be established and stored. All investigators were trained with the electronic data system and regular monitoring visits are held to ensure proper data quality. Data management will be done by M.L. and W.M. Forwarding of patient-related data for further statistical analyses will only be done in pseudonymized or anonymized form. The code which enables the pseudonymized data to be allocated to a particular individual will be stored at the respective study centers. Following the completion of statistical analyses, data will be stored for 15 years in accordance with the “International Conference of Harmonization – Good Clinical Practice (ICH-GCP)” guidelines. All data will be handled in accordance with the EU General Data Protection Regulation and/or applicable national data protection regulations. Parents of study participants will be informed about their data protection rights in the informed consent form and written consent will be obtained.

Safety
Preterm infants, and especially those born very and extremely premature, are an exceptionally vulnerable and often seriously ill patient population. Many adverse events (AEs) seen in this collective may be of serious nature. However, most of these AEs are expected to occur with no relationship to the intervention performed during the NEOVASC trial. In addition, the use of human milk and a human-milk-based fortifier (Humavant™) in preterm infants is based on years of prior experience in clinical routine. Given that this is a nutritional study using a routinely used feeding product in the absence of
pharmacological interventions, the investigators decided to move forward without an independent “Data Safety and Monitoring Board (DSMB)” prior to the study’s initiation and an interim analysis or stopping guidelines were not included in the current study design. AEs may be defined as medical NEC, confirmed late-onset sepsis as identified by positive blood cultures and feeding intolerance resulting in NPO status ≥ 24 h, change to infant formula, bloody stools, bilious emesis, or severe abdominal distension that results in a change with clinical nutritional management of the patient. Severe adverse events (SAEs) may be defined as death, surgical NEC, and lengthening of hospitalization. All SAEs and suspected unexpected serious adverse reactions (SUSARs) will be reported to the respective local ethics committee. If in the opinion of the attending physician there is a reasonable likelihood that any AE may have been causally associated with products from Prolacta Bioscience, Inc., or if the event results in a death regardless of the likelihood of association, Prolacta Bioscience, Inc., will additionally be notified and further clinical actions will be taken depending on the nature of the incident and the certainty of their causal relationship to the study product or study-specific procedures, respectively.

Informed consent procedure and withdrawal
Expecting parents of potential participants will be invited by the respective principal investigators and/or explicitly permitted colleagues to enroll their preterm infants before or in a timely manner after delivery. Since additional data on the course of pregnancy will be gathered as well, written informed consent about the participation of preterm infants must be explicitly obtained from the infant’s mother. As for study participants in the term-born control group, written informed consent can be obtained from either parent or legal guardian. Subjects and their legal guardians have the right to withdraw consent fully or partially at any time and for any reason. All data until the point of withdrawal will be included in the final analysis. However, no further information will be collected. Protocol changes will be communicated to interested parties using the clinicaltrials.gov platform. Whenever protocol changes will affect study participants, informed consent will be obtained using an updated informed consent form.

Ethics and trial registration
This protocol and all related documents have been approved by the ethics committee at each respective study site. The NEOVASC trial will be conducted in accordance with the Declaration of Helsinki in its most recent form and ICH-GCP guidelines. This study has been prospectively registered at clinicaltrials.gov (NCT04413994).

Discussion
Given the abovementioned increasing preterm birth rates coupled with improvements in perinatal care and therefore low neonatal mortality rates, increases in long-term morbidities in formerly preterm infants are poised to become major public health challenges. This increased cardiovascular risk in formerly preterm infants may further strengthen the impact of CVDs as the world’s leading cause of death. A very recent Swedish population-based study of young male and female military conscripts found that formerly preterm infants were significantly more likely to exhibit elevated BP levels and an increased relative risk of systolic hypertension (defined as systolic BP ≥ 140 mmHg) in young adulthood when compared to those born at full- or post-term. The adjusted relative risk of developing systolic hypertension was 1.72 and 1.22 for female and male conscripts, respectively. For both women and men, an inverse relationship between gestational age and BP levels was observed [13]. These results corroborate previous findings in Swedish male military conscripts [36]. Another national cohort study from Sweden also found markedly increased risks of developing hypertension (defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or taking antihypertensive medication) in young adulthood following preterm birth. This study also demonstrated an inverse correlation between gestational age and relative risk of developing hypertension. Therefore, formerly extremely preterm infants had a 1.8-fold risk of developing hypertension relative to infants born full-term (39–41 weeks’ gestation) [18]. These results find support in previously conducted meta-analyses on the association between preterm birth and elevated BP levels [14, 15]. With regard to the association between preterm birth and diabetes mellitus, a Swedish national cohort study found that the risk of developing type 1 or type 2 diabetes mellitus in young adulthood following preterm birth was 1.24 and 1.49, respectively when compared to infants born full-term. This study also found an inverse correlation between gestational age and risk of developing type 1 or type 2 diabetes mellitus. Extremely preterm birth was therefore associated with > 2-fold risks of developing both type 1 and type 2 diabetes mellitus [20]. These results find support in a previously conducted meta-analysis by Li et al. [19]. Both hypertension [37] and diabetes mellitus [38] are independent risk factors for the development of cardiovascular events. In addition to the abovementioned findings, a direct association between preterm birth and cardiovascular events later in life has been demonstrated. As for a CVD composite outcome consisting of ischemic heart disease, heart failure, cerebrovascular disease, and cardiovascular-related death, the risks of developing either one of these outcomes in the age group of 0–43 years were 1.57 and 5.68.
for all preterm birth and extremely preterm birth, respectively, when compared to full-term birth [18]. Another study by Crump et al. [39] also found that preterm birth was significantly associated with ischemic heart disease in adulthood. Both studies [18, 19] further noticed an inverse correlation between gestational age and the development of cardiovascular events.

In conclusion, preterm birth has been shown to be associated with an adverse outcome in terms of cardiovascular health. While the benefits of an exclusive human-milk diet in preterm infants have been suggested for outcomes such as rates of NEC, duration of parenteral nutrition, risk of late-onset sepsis, and mortality [24–27], less is known about its effects on cardiovascular and metabolic risk factors. Given the emerging implications of an increased cardiovascular risk profile in the possibly steadily growing population of preterm infants, further research on the mitigation of long-term morbidities in formerly preterm infants is urgently warranted.

**Trial status**

**Protocol Version 4.7 (19 May 2020)**

- **Trial status:** Recruiting (first patient on 7 October 2020)
- **Study duration:** Recruitment period of 36 months, follow-up until 5 years of age.

**Abbreviations**

AE: Adverse event; ALAT/ALT: Alanine aminotransferase; ASAT/AST: Aspartate transaminase; BP: Blood pressure; CRP: C-reactive protein; CVD: Cardiovascular disease; GOT: Glutamic oxaloacetic transaminase; GPT: Glutamate pyruvate transaminase; HDL: High-density lipoprotein; HOMA: Homeostasis model assessment; ICH-GCP: International Conference of Harmonization – Good Clinical Practice; IL-6: Interleukin-6; LDL: Low-density lipoprotein; NCD: Noncommunicable disease; NEC: Necrotizing enterocolitis; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; NOP: Nil per os; SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials; SUASAR: Suspected unexpected serious adverse reaction; TSH: Thyroid-stimulating hormone; WHO: World Health Organization; y-GT: Gamma-glutamyltransferase

**Supplementary information**

The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05445-9.

---

Additional file 1: Figure S1. Trial flow chart.

Additional file 2. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

**Acknowledgements**

This study is supported by VASCage – Research Centre on Vascular Ageing and Stroke. As a COMET centre VASCage is funded within the COMET program - Competence Centres for Excellent Technologies by the Austrian Ministry for Digital and Economic Affairs and the federal states Tyrol, Salzburg, and Vienna.

**Authors’ contributions**

U.K.K. is the coordinating investigator of the NEOVASC clinical trial, conceived the study, led the proposal, and authored the study protocol. C.B., A.B-E., L.A-H., A.B., B.S., M.W., and M.L. all contributed to the study design and to development of the study protocol and all related documents. U.K.K. (Innsbruck), M.W. (Salzburg), C.B. (Vienna), and B.S. (Feldkirch) are the principal investigators at their respective study sites. M.L. is further the study’s statistician and responsible for the conceptualization of the statistical plan. W.M. authored the present manuscript for the publication of the NEOVASC study protocol. The final manuscript was read and approved by all authors.

**Funding**

Prolacta Bioscience, Inc. acts as the sponsor and funding body for the present study. They provide both free human-milk-based fortifiers (Huma-vent<sup>®</sup>) and monetary support for the conduct of the NEOVASC trial. Legal representative for Prolacta Bioscience, Inc., in the EU is Mr. Vincent Gaspar (Email: vgaspar@prolacta.com, phone: +32 2 893 7359).

**Declarations**

**Ethics approval and consent to participate**

The present study was approved by the ethics committees of all four study sites (Ethics Committee of the Medical University of Innsbruck, Ethics Committee of the Federal State Salzburg, Ethics Committee of the Medial University of Vienna and Vienna General Hospital, Ethics Committee of the Federal State Vorarlberg). Written informed consent prior to enrollment will be obtained for all participants.

**Consent for publication**

The authors are willing to provide an English version of the informed consent form if requested. A designated “Biosampling Manual” concerning all biosampling procedures related to the NEOVASC trial can also be submitted on request.

**Competing interests**

M.L. is an employee of Prolacta Bioscience, Inc. The authors declare that they have no further competing interests.

**Author details**

1VASCage GmbH, Research Centre on Vascular Ageing and Stroke, Innrain 66a, 6020 Innsbruck, Austria. 2Department of Pediatrics II (Neonatology), Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria. 3Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Division of Neonatology, Pediatric Intensive Care & Neonopediatrics, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. 4Department of Pediatrics, Academic Teaching Hospital Feldkirch, Carinagasse 47, 6800 Feldkirch, Austria. 5Department of Pediatrics, Division of Neonatology, Paracelsus Medical University Salzburg, Strubergasse 21, 5020 Salzburg, Austria. 6Fielding School of Public Health (UCLA), 650 Charles E. Young Dr. South, Los Angeles, CA 90095-1772, USA. 7Prolacta Bioscience, 1800 Highland Ave, Duarte, CA 91010, USA.

**Received:** 20 March 2021 **Accepted:** 10 July 2021 **Published online:** 31 July 2021

**References**

1. GBD 2017 Caused of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736–88.
2. World Health Organization. Noncommunicable diseases country profiles 2018. https://apps.who.int/iris/handle/10665/274512. License: CC BY-NC-SA 3.0 IGO.
3. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993; 341(8850):938–41.
4. Barker DP. The developmental origins of chronic adult disease. Acta Paediatr Suppl. 2004;93(446):26–33.
5. Crump C, Winkleby MA, Sundquist J, Sundquist K. Prevalence of survival without major comorbidities among adults born prematurely. JAMA. 2019; 322(16):1580–8.
6. Raju TNK, Buist AS, Bialedss CI, Moxey-Mims M, Saigal S. Adults born preterm: a review of general health and system-specific outcomes. Acta Paediatr. 2017;106(9):1409–37.

---
7. Crump C, Sundquist K, Sundquist J, Winkley MA. Gestational age at birth and mortality in young adulthood. JAMA. 2011;306(11):1233–40.

8. Crump C, Sundquist J, Winkley MA, Sundquist K. Gestational age at birth and mortality from infancy into mid-adulthood: a national cohort study. Lancet Child Adolesc Health. 2019;3(6):408–17.

9. Katz J, Lee AC, Kozuki N, Law J, Coussens S, Blencowe H, et al. Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013;382(9890):417–25.

10. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019; 7(1):e7–46.

11. Iams JD, Romero R, Culhane JF, Goldberg RL. Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet. 2008;371(9607):164–75.

12. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA. 2015;314(18):1939–51.

13. Skudder-Hill L, Ahlsson F, Lundgren M, Cutfield WS, Derraik JGB. Preterm birth is associated with increased blood pressure in young adult women. J Am Heart Assoc. 2019;8(12):e012274.

14. de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension. 2012;59(2):226–34.

15. Markopoulou P, Papanikolau E, Analytis A, Zoumakis E, Siahanidou T. Preterm birth and risk of cardiovascular disease in adult life: a systematic review and meta-analysis. J Pediatr. 2019; 210:69–80.e5.

16. Parkinson JRC, Hyde MJ, Gale C, Santhakumaran S, Modi N. Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis. Pediatr. 2013;131(4):e1240–63.

17. Li S, Xi B. Preterm birth is associated with risk of essential hypertension in later life. Int J Cardiol. 2014;172(2):e361–3.

18. Crump C, Sundquist J, Sundquist K. Risk of hypertension into adulthood in persons born prematurely: a national cohort study. Eur J Heart. 2020;41(16):1542–50.

19. Li S, Zhang M, Tian H, Liu Z, Yin X, Xi B. Preterm birth and risk of type 1 and type 2 diabetes: systematic review and meta-analysis. Obes Rev. 2014;15(10):1084–111.

20. Crump C, Sundquist J, Sundquist K. Preterm birth and risk of type 1 and type 2 diabetes: a national cohort study. Diabetologia. 2020;63(3):508–18.

21. Odri Komazec I, Posod A, Schwienbacher M, Reich M, Pupp Peglow U, Kiechl S, et al. Aortic elastic properties in preschool children born preterm. Arterioscler Thromb Vasc Biol. 2016;36(11):2268–74.

22. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular disease in adult life: a systematic review and meta-analysis. Pediatr. 2019;172(2):e361–3.

23. Victora CG, Bahl R, Barros AJD, Franca GVA, Horton S, Krasevec J, et al. Multidisciplinary approaches to improve breastfeeding outcomes: a systematic review and meta-analysis. Lancet. 2014;383(9929):960–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more biomedcentral.com/submissions